摘要
目的:应用双通道技术联合眼表综合分析仪评价重组人表皮生长因子(rhEGF)衍生物滴眼液治疗中度干眼伴浅层点状角膜病变(SPK)的效果,并评判治疗前后视觉质量的变化。方法:选择中度干眼伴SPK患者48例(96眼),随机分为治疗组和对照组。治疗组使用人工泪液联合rhEGF衍生物滴眼液治疗,对照组单用人工泪液治疗,记录治疗前、治疗后(3±1)d、(7±1)d、(14±2)d、(28±1)d角膜荧光染色(FL)消失率、眼表指数评分(OSDI)调查问卷、泪液分泌实验(Schimer-ⅠTest,SⅠT)、眼表综合分析仪相关参数(结膜充血程度评分、泪河高度、泪膜破裂时间(BUT))、双通道视觉质量分析系统(OQAS)相关参数[调制传递函数(MTF)截止频率(MTF cut off)、斯特列尔比(SR)、客观散射指数(OSI)均值及标准差]。结果:治疗前,治疗组与对照组各指标差异均无统计学意义(P>0.05);治疗后(3±1)d、(7±1)d、(14±2)d、(28±1)d两组各指标差异均有明显统计学意义(P<0.05)。结论:rhEGF衍生物滴眼液联合人工泪液能有效改善中度干眼伴SPK的临床症状及体征,并能显著提高患者的视觉质量,效果优于单用人工泪液;眼表综合分析仪及OQAS提供客观量化的指标,可辅助医生对患者进行个性化治疗。
Objective： To use double-pass technology combined ocular surface analyzer to evaluate the effect of recombinant human epidermal growth factor （rhEGF） derivative eye drops in treatment of moderate dry eye with superficial punctate keratopathy （SPK）, and to evaluate the visual qual- ity before and after treatment. Methods： 48 examples （96 eyes） with moderate dry eye and SPK were selected and randomly divided into treatment group and control group. In the treatment group, the patients were treated by deriviatives of rhEGF and artificial tears eyedrops. In the control group, the patients were treated by artificial tears. The disappearance rate of corneal fluorescence staining （FL）, scores of ocular surface disease index（OSDI）, Schimer- I Test （S I T）, related parameters of ocular surface analyzer （scores of conjunctival congestion, lacrimal river height, tear break-up time E BUT]）, related parameters of optical quality analysis system （OQAS） （modulation transfer function cut off （MTF cut off）, Strehl ratio （SR）, mean and standard deviation of objective scatter index （OSI） were recorded before and after （3±1） d, （7± 1） d, （14±2） d, （28± 1） d treatment. Results： There was no statistical difference between the two groups before treatment （P〉0.05）. After the treatment, all parameters were significantly different （P〈0.05）. Conclusion： Derivatives of rhEGF combined with artificial tears eyedrops can effectively improve the clinical symptoms, asymptomatic and visual quality in the patients with moderate dry eye and SPK, and the effect is better than the single artificial tears. Ocular surface analyzer and OQAS provide objective quantitative indicators, which can assist doctor to offer individualized treatment for patients.
出处
《武汉大学学报（医学版）》
CAS
2017年第4期622-628,663,共8页
Medical Journal of Wuhan University
关键词
中度干眼
浅层点状角膜病变
重组人表皮生长因子
人工泪液
眼表综合分析仪
双通道技术
Moderate Dry Eye
Superficial Punctate Keratopathy
Recombinant Human Epidermal Growth Factor
Artificial Tears
Ocular Surface Analyzer
Double-pass Technology
